newsfilter
← Earnings
Earnings Releases·

Cytokinetics — Third Quarter 2026 Earnings Summary

Cytokinetics reported third-quarter 2026 net product revenue of $44.5 million from MYQORZO (aficamten), bringing total revenues to $47.6 million. The company achieved approximately $1.6 billion in cash, cash equivalents, and investments as of September 30, 2026, while reporting a net loss of $190.1 million for the quarter. MYQORZO received marketing authorization in the United Kingdom and Canada, and the company plans to submit a Supplemental New Drug Application for non-obstructive hypertrophic cardiomyopathy in the fourth quarter of 2026. Additionally, Cytokinetics reaffirmed its full-year 2026 financial guidance for combined research and development and selling, general, and administrative expenses between $860 million and $890 million.

Company
CYTOKINETICS INC
Sector
Healthcare
Industry
Biotechnology